{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T21:04:54Z","timestamp":1776114294236,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clgc.2026.102516","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T08:12:59Z","timestamp":1770624779000},"page":"102516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective, Observational Analysis of Real-World Safety Outcomes in Patients With Locally Advanced\/Metastatic Urothelial Cancer Treated With Sacituzumab Govitecan"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7300-7452","authenticated-orcid":false,"given":"Mamta","family":"Parikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freda","family":"Boateng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Ghazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Brockman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7138-2638","authenticated-orcid":false,"given":"Xinran","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"Sierecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102516_bib0001","unstructured":"National Cancer Institute, Surveillance, epidemiology, and end results program. Cancer stat facts: bladder cancer. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed: November 20, 2024."},{"issue":"4","key":"10.1016\/j.clgc.2026.102516_bib0002","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jnci\/djad246","article-title":"Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment","volume":"116","author":"Gupta","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.clgc.2026.102516_bib0003","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102516_bib0004","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/cancers13010131","article-title":"Immune checkpoint inhibitors for the treatment of bladder cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.clgc.2026.102516_bib0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.clgc.2026.102516_bib0006","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2026.102516_bib0007","unstructured":"Gilead Sciences. Gilead provides update on U.S. indication for Trodelvy\u00ae in metastatic urothelial cancer. Available at: https:\/\/www.gilead.com\/company\/company-statements\/2024\/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer. Accessed: April 25, 2025."},{"key":"10.1016\/j.clgc.2026.102516_bib0008","doi-asserted-by":"crossref","unstructured":"Grivas P, Powles T, Vulsteke C, et al. TROPiCS-04: a randomized phase 3 study of sacituzumab govitecan vs chemotherapy in pretreated advanced urothelial carcinoma. Presented at: European Society for Medical Oncology (ESMO) Asia; European Society for Medical Oncology (ESMO) Asia Congress; December 6-8, 2024; Singapore, Republic of Singapore.","DOI":"10.1016\/j.annonc.2024.10.830"},{"issue":"5","key":"10.1016\/j.clgc.2026.102516_bib0009","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102516_bib0010","unstructured":"Flatiron Health. Database characterization guide. Available at: https:\/\/flatiron.com\/database-characterization. Accessed: April 24, 2025."},{"key":"10.1016\/j.clgc.2026.102516_bib0011","unstructured":"TRODELVY\u00ae (Sacituzumab govitecan-hziy) [prescribing information]. Foster City, CA Gilead Sciences, Inc 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761115s000lbl.pdf"},{"issue":"21","key":"10.1016\/j.clgc.2026.102516_bib0012","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2217\/fon-2023-0513","article-title":"The impact of myelosuppression on quality of life of patients treated with chemotherapy","volume":"20","author":"Crawford","year":"2024","journal-title":"Future Oncol"},{"issue":"29","key":"10.1016\/j.clgc.2026.102516_bib0013","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.23.01720","article-title":"TROPHY-U-01 cohort 2: a phase II study of sacituzumab govitecan in cisplatin-ineligible patients with metastatic urothelial cancer progressing after previous checkpoint inhibitor therapy","volume":"42","author":"Petrylak","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102516_bib0014","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","article-title":"Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom","volume":"130","author":"Hanna","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2026.102516_bib0015","first-page":"9","article-title":"Real-world outcomes of sacituzumab govitecan in metastatic breast cancer patients: a single institution experience","volume":"37","author":"Alaklabi","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.clgc.2026.102516_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1362641","article-title":"Sacituzumab govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis","volume":"14","author":"Caputo","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102516_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231200454","article-title":"Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany","volume":"15","author":"Reinisch","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2026.102516_bib0018","doi-asserted-by":"crossref","first-page":"P4-07-56","DOI":"10.1158\/1538-7445.SABCS22-P4-07-56","article-title":"Abstract P4-07-56: Mayo clinic enterprise patterns of growth-factor utilization for sacituzumab govitecan (SG)-induced neutropenia among patients with metastatic triple negative breast cancer","volume":"83","author":"Clark","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2026.102516_bib0019","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-024-07412-9","article-title":"Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States","volume":"208","author":"Kalinsky","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102516_bib0020","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2024.42.16_suppl.3029","article-title":"Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types","volume":"42","author":"Rugo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clgc.2026.102516_bib0021","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102516_bib0022","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102516_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103725","article-title":"The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria","volume":"9","author":"Apolo","year":"2024","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.clgc.2026.102516_bib0024","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102516_bib0025","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/JCO.2025.43.16_suppl.4501","article-title":"Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): interim analysis from the JAVELIN Bladder Medley phase 2 trial","volume":"43","author":"Hoffman-Censits","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102516_bib0026","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/JCO.2025.43.16_suppl.4518","article-title":"First results of SURE-02: a phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC)","volume":"43","author":"Necchi","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:45:25Z","timestamp":1776109525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1558767326000169"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102516","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective, Observational Analysis of Real-World Safety Outcomes in Patients With Locally Advanced\/Metastatic Urothelial Cancer Treated With Sacituzumab Govitecan","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102516"}}